Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
Clinical trial NCT06003387 · RECRUITING
Trial details
- NCT number
- NCT06003387
- Sponsor
- CSL Behring
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-30
- Primary completion
- 2028-10-04
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.